Skip to Main Content

Hello, everyone, and welcome to the middle of the week. You made it this far, so why not acknowledge the moment with a non-carcinogenic cup of stimulation? After all, consider the alternatives. Before we continue, we would like to note that we will take an extended break to attend to a milestone for the shortest of our short people. We will return next week. Meanwhile, we hope you have a productive couple of days and a delightful weekend. And now, here are some tidbits. Stay well, y’all …

The American Diabetes Association let hundreds, possibly thousands, of attendees see new study data on Novo Nordisk’s Victoza diabetes drugs more than an hour before its official release to the public and the markets, Bloomberg News says. The attendees were asked not to tweet the info, but — surprise! — some folks tweeted pictures of charts within minutes.

advertisement

Federal incentives to drug makers have helped lead to at least seven late-stage antibiotics that may fight bacteria that can become dangerous superbugs, the Wall Street Journal writes. “We have built a robust portfolio of broad-spectrum antibiotics that possess activity” against the microbes, Richard Hatchett, acting director of the government’s Biomedical Advanced Research and Development Authority, told lawmakers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.